Loading...
| A03181 | Pages: NA | Jul 2022 | 5934 Views | | |
| Author(s) : NA | Tables: NA | Charts: NA |
| |
Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the Swine Health Market
Request Now !Swine health is associated with the diseases caused due to pigs and the development of therapeutics to prevent the related ailments and disorders. Pig breeding can lead to many diseases such as reproductive disease and congenital malformations. Hence, governmental organizations are launching programs to protect and enhance the health of swine, which reduces the effect of swine diseases on humans.
Increase in incidences of diseases through swine drive the market. However, high cost associated with swine health especially in the developing countries impede the market growth. Moreover, key market players investing in R&D activities to develop novel therapeutics to address unmet medical needs create lucrative opportunities.
Swine health market is segmented based on diseases, route of administration, and geography. Based on diseases, the market is divided into aujeszkys disease (AD), classical swine fever (CSF), actinobacillus pleuropneumonia, mycoplasma hyopneumoniae, swine enteric coronavirus disease, porcine reproductive and respiratory syndrome (PRRS), and salmonella. Based on route of administration, the market is classified into injectable and oral. By geography, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Comprehensive competitive analysis and profiles of major market players such as Neogen Co, Norbrook Group, Orion Pharma, Phibro Animal Health, Vetoquinol Animal Health Pvt Ltd, Bio-Vet, Dechra Pharmaceuticals PLC, ECO Animal Health, Huvepharma SEA Private Limited, and Indian Immunologicals are provided in this report.
Key Benefits
Key Market Segments
| Segments | Sub-segments |
|---|---|
| By Disease |
|
| By Route of Administration |
|
| By Region |
|
Key Market Players
CHAPTER 1 INTRODUCTION
1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models
CHAPTER 2 EXECUTIVE SUMMARY
2.1. CXO PERSPECTIVE
CHAPTER 3 MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. MARKET SHARE ANALYSIS/TOP PLAYER POSITIONING, 2016
3.4. PORTER’S FIVE FORCES ANALYSIS
3.5. MARKET DYNAMICS
3.5.1. Drivers
3.5.2. Restraints
3.5.3. Opportunities
CHAPTER 4 SWINE HEALTH MARKET, BY DISEASE
4.1. OVERVIEW
4.1.1. Market size and forecast
4.2. AUJESZKY'S DISEASE (AD)
4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast
4.3. CLASSICAL SWINE FEVER (CSF)
4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast
4.4. ACTINOBACILLUS PLEUROPNEUMONIA
4.4.1. Key market trends
4.4.2. Growth factors and opportunities
4.4.3. Market size and forecast
4.5. MYCOPLASMA HYOPNEUMONIAE
4.5.1. Key market trends
4.5.2. Growth factors and opportunities
4.5.3. Market size and forecast
4.6. SWINE ENTERIC CORONAVIRUS DISEASE
4.6.1. Key market trends
4.6.2. Growth factors and opportunities
4.6.3. Market size and forecast
4.7. PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME (PRRS)
4.7.1. Key market trends
4.7.2. Growth factors and opportunities
4.7.3. Market size and forecast
4.8. SALMONELLA
4.8.1. Key market trends
4.8.2. Growth factors and opportunities
4.8.3. Market size and forecast
CHAPTER 5 SWINE HEALTH MARKET, BY ROUTE OF ADMINISTRATION
5.1. OVERVIEW
5.1.1. Market size and forecast
5.2. INJECTABLE
5.2.1. Key market trends
5.3. ORAL
5.3.1. Key market trends
CHAPTER 6 SWINE HEALTH MARKET, BY REGION
6.1. OVERVIEW
6.2. NORTH AMERICA
6.2.1. Key market trends
6.2.2. Key growth factors and opportunities
6.2.3. Market size and forecast
6.2.3.1. U.S. market size and forecast
6.2.3.2. Canada market size and forecast
6.2.3.3. Mexico market size and forecast
6.2.4. North America Swine Health Market by Disease
6.2.5. North America Swine Health Market by Route of Administration
6.3. EUROPE
6.3.1. Key market trends
6.3.2. Key growth factors and opportunities
6.3.3. Market size and forecast
6.3.3.1. Germany market size and forecast
6.3.3.2. France market size and forecast
6.3.3.3. UK market size and forecast
6.3.3.4. Spain market size and forecast
6.3.3.5. Rest of Europe market size and forecast
6.3.4. Europe Swine Health Market by Disease
6.3.5. Europe Swine Health Market by Route of Administration
6.4. ASIA-PACIFIC
6.4.1. Key market trends
6.4.2. Key growth factors and opportunities
6.4.3. Market size and forecast
6.4.3.1. Japan market size and forecast
6.4.3.2. China market size and forecast
6.4.3.3. Australia market size and forecast
6.4.3.4. India market size and forecast
6.4.3.5. Rest of Asia-Pacific market size and forecast
6.4.4. Asia-Pacific Swine Health Market by Disease
6.4.5. Asia-Pacific Swine Health Market by Route of Administration
6.5. LAMEA
6.5.1. Key market trends
6.5.2. Key growth factors and opportunities
6.5.3. Market size and forecast
6.5.3.1. Brazil market size and forecast
6.5.3.2. Turkey market size and forecast
6.5.3.3. Saudi Arabia market size and forecast
6.5.3.4. South Africa market size and forecast
6.5.3.5. Rest of LAMEA market size and forecast
6.5.4. LAMEA Swine Health Market by Disease
6.5.5. LAMEA Swine Health Market by Route of Administration
CHAPTER 7 COMPANY PROFILES
7.1. NEOGEN CO
7.1.1. Operating business segments
7.1.2. Business performance
7.1.3. Key strategic moves and developments
7.2. NORBROOK GROUP
7.2.1. Operating business segments
7.2.2. Business performance
7.2.3. Key strategic moves and developments
7.3. ORION PHARMA
7.3.1. Operating business segments
7.3.2. Business performance
7.3.3. Key strategic moves and developments
7.4. PHIBRO ANIMAL HEALTH
7.4.1. Operating business segments
7.4.2. Business performance
7.4.3. Key strategic moves and developments
7.5. VETOQUINOL ANIMAL HEALTH PVT LTD
7.5.1. Operating business segments
7.5.2. Business performance
7.5.3. Key strategic moves and developments
7.6. BIO-VET
7.6.1. Operating business segments
7.6.2. Business performance
7.6.3. Key strategic moves and developments
7.7. DECHRA PHARMACEUTICALS PLC
7.7.1. Operating business segments
7.7.2. Business performance
7.7.3. Key strategic moves and developments
7.8. ECO ANIMAL HEALTH
7.8.1. Operating business segments
7.8.2. Business performance
7.8.3. Key strategic moves and developments
7.9. HUVEPHARMA SEA PRIVATE LIMITED
7.9.1. Operating business segments
7.9.2. Business performance
7.9.3. Key strategic moves and developments
7.10. INDIAN IMMUNOLOGICALS
7.10.1. Operating business segments
7.10.2. Business performance
7.10.3. Key strategic moves and developments
Clients can easily download both quantitative as well as
qualitative reports in PDF and excel formats.
Start reading.
This Report and over 13,000+ thousand more Reports, Available with Avenue Library. T&C*.
Enterprise
License/PDF
Buy Now *Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
